Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Qdenga® - A promising dengue fever vaccine; can it be recommended to non-immune travelers?

Angelin, Martin ; Sjölin, Jan ; Kahn, Fredrik LU ; Ljunghill Hedberg, Anna ; Rosdahl, Anja ; Skorup, Paul ; Werner, Simon LU ; Woxenius, Susanne and Askling, Helena H. (2023) In Travel Medicine and Infectious Disease 54.
Abstract

Qdenga® has been approved by the European Medicines Agency (EMA) for individuals > 4 years of age and for use according to national recommendations. The vaccine shows high efficacy against virologically confirmed dengue and severe dengue in clinical studies on 4–16-year old's living in endemic areas. For individuals 16–60 years old only serological data exists and there is no data for individuals > 60 years. Its use as a travel vaccine is still unclear. We present the studies behind the approval and the recommendations for travelers as issued by the Swedish Society for Infectious Diseases Physicians.

Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Travel Medicine and Infectious Disease
volume
54
article number
102598
publisher
Elsevier
external identifiers
  • pmid:37271201
  • scopus:85161309981
ISSN
1477-8939
DOI
10.1016/j.tmaid.2023.102598
language
English
LU publication?
yes
id
4ea52021-2404-4b20-b8e1-46385f7f7d5a
date added to LUP
2023-08-17 10:22:24
date last changed
2024-06-16 08:33:44
@article{4ea52021-2404-4b20-b8e1-46385f7f7d5a,
  abstract     = {{<p>Qdenga® has been approved by the European Medicines Agency (EMA) for individuals &gt; 4 years of age and for use according to national recommendations. The vaccine shows high efficacy against virologically confirmed dengue and severe dengue in clinical studies on 4–16-year old's living in endemic areas. For individuals 16–60 years old only serological data exists and there is no data for individuals &gt; 60 years. Its use as a travel vaccine is still unclear. We present the studies behind the approval and the recommendations for travelers as issued by the Swedish Society for Infectious Diseases Physicians.</p>}},
  author       = {{Angelin, Martin and Sjölin, Jan and Kahn, Fredrik and Ljunghill Hedberg, Anna and Rosdahl, Anja and Skorup, Paul and Werner, Simon and Woxenius, Susanne and Askling, Helena H.}},
  issn         = {{1477-8939}},
  language     = {{eng}},
  publisher    = {{Elsevier}},
  series       = {{Travel Medicine and Infectious Disease}},
  title        = {{Qdenga® - A promising dengue fever vaccine; can it be recommended to non-immune travelers?}},
  url          = {{http://dx.doi.org/10.1016/j.tmaid.2023.102598}},
  doi          = {{10.1016/j.tmaid.2023.102598}},
  volume       = {{54}},
  year         = {{2023}},
}